CD19 and neoplasm: Moreover, their abilities to kill 4T1-mCD19 cells reached 100% efficiency at an effector to tumor cell ratio of 5:1 (Figure 2B), even though nontransduced T cells lacking the anti-CD19 CAR displayed insignificant cytotoxicity against the same CD19+ tumor cell clones (panel B).